ARTHROPLASTY
AAOS 2016: Liposomal vs standard bupivacaine in TKA; no difference in analgesic efficacy
162 patients scheduled for primary total knee arthroplasty were randomized to periarticular injections with either liposomal bupivacaine or standard bupivacaine. Pain scores and narcotic consumption were recorded over the first 4 postoperative days while function and health-related quality of life were assessed at 4-6 weeks postoperatively. Results demonstrated no significant difference between groups in any assessed outcome.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
